Led · Seed · Jan 2026

EncephalX is a Sherbrooke-based medical technology venture focused on redefining post-trauma and post-stroke cranial care through its flagship Dynamic Cranioplasty System (DCPS). The DCPS replaces the current two-stage craniectomy/cranioplasty workflow with a single operation that offers continuous intracranial pressure decompression, aiming to improve patient outcomes and shorten hospital stays. The technology originated from academic research into cranial defects and has been refined in close collaboration with practicing neurosurgeons, including the company’s medical director, Dr. Christian Iorio-Morin. Management plans to use its newly raised capital to achieve the first-in-human implantation and advance regulatory approval of the fully developed surgical kit. Longer-term goals include building additional clinical, regulatory, and industrial partnerships and expanding the platform internationally. No revenue or user metrics have been disclosed to date.

Participated · Seed · Dec 2024

Nurau develops AI-powered conversational coaching tools for managers, with a flagship product called eCoach that provides real-time suggestions, predictive responses and policy-aligned guidance. The platform is designed to help managers navigate sensitive workplace discussions, reduce escalations, improve employee engagement and minimize turnover costs. Nurau was founded by Justin Lessard-Wajcer, Sonia Israel and Saba Saremi and is based in Montreal. The company recently raised capital and is using funds to accelerate growth and go-to-market activities. Proceeds will support expansion into the U.S., bolster sales development, and target retail and manufacturing clients. Financially, Nurau completed a seed financing and intends to extend the round in the near term.

Participated · Seed · Sep 2021

Gallea operates an online art distribution platform that helps artists bring their works to art lovers and aims to democratize access to art. The company is described in the press release as the largest art distribution network in Canada and plans to expand to become the largest such network worldwide. Gallea closed a C$1.5M pre-seed financing led by THCap to support that expansion. The round included Canadian VCs and funds as well as international investors and business angels. Investors named in the article include Real Ventures, ACET Capital, Anges Québec, National Social Value Fund, Dispatch Ventures, Telegraph Hill Capital (Barcelona), Manford Technologies (California) and various business angels from Canada, California (U.S.) and Shandong (China). According to Telegraph Hill Capital’s managing partner quoted in the article, Gallea has delivered on its vision over the prior six months and showed strong execution.

Led · Equity · Jan 2016

BioIntelligence Technologies, based in Sherbrooke, QC, Canada, develops AI-powered instruments and software to monitor, understand, predict, and optimize industrial bioprocesses using fermentation. Its core product, the BioIntelligence Analytics Solution™ (BAS™), measures microorganism evolution, nutrient consumption, and product synthesis directly in fermenters and bioreactors and performs advanced customized analytics in real time for plant operators. BAS™ is already commercial with industrial clients in North America and Europe. The company says its solutions reduce product losses, cut water and energy consumption, and lower CO2 emissions while improving consistency and profitability for industrial clients. Led by CEO and founder Joel Sirois, BioIntelligence creates and commercializes intelligent instruments and software for biotech companies. It raised $5M to accelerate growth in America and Europe. Founded in 2014 and based in Sherbrooke, BioIntelligence Technologies has developed two proprietary technology platforms and licensed a third from the University of Sherbrooke to optimize biological processes in real time. Its smart probes and server-analysts (the BioAnalyst product) monitor multiple key variables and recommend actions to maximize the profitability of biological cultures. The company completed a first financing round to support commercialization of the BioAnalyst and to accelerate development of additional products. Management says initial commercial targets are industrial biotechnology customers in the U.S. and Europe, with biopharmaceuticals targeted later at a global scale. BioIntelligence operates from the Espace-INC incubator and has received local acceleration support from Sherbrooke Innopole and ACET. The company has also won regional entrepreneurial awards and competitions in 2015.